An age‐dependent mathematical model of neurofilament trafficking in healthy conditions-Reference-Cited by-同舟云学术

An age‐dependent mathematical model of neurofilament trafficking in healthy conditions

Published:2022-03-02 Issue:4 Volume:11 Page:447-457
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Paris Alessio¹,Bora Pranami¹,Parolo Silvia¹,Monine Michael²,Tong Xiao²,Eraly Satish²,Masson Eric²,Ferguson Toby²,McCampbell Alexander²,Graham Danielle²,Domenici Enrico¹³,Nestorov Ivan²,Marchetti Luca¹³

Affiliation:

1. Fondazione The Microsoft Research – University of Trento Centre for Computational and Systems Biology Rovereto Italy

2. Biogen, Inc. Cambridge Massachusetts USA

3. Department of Cellular, Computational and Integrative Biology University of Trento Trento Italy

Funder

Biogen

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12770

Reference37 articles.

1. Review of the Multiple Aspects of Neurofilament Functions, and their Possible Contribution to Neurodegeneration

2. The dazzling rise of neurofilaments: Physiological functions and roles as biomarkers

3. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls

4. Serum neurofilament light levels in normal aging and their association with morpohologic brain changes. Nat;Khalil M;Commun,2020

5. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington's disease: a semi-mechanistic model-based analysis;Frontiers in Neuroscience;2024-07-03

2. The dynamic of changes of pNFH levels in the CSF compared with the motor scales’ scores during three years of nusinersen treatment in children with spinal muscular atrophy types 2 and 3;Balneo and PRM Research Journal;2024-03-31

3. Advancing precision medicine therapeutics for Parkinson’s utilizing a shared quantitative systems pharmacology model and framework;Frontiers in Systems Biology;2024-03-08

4. Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era;Frontiers in Neurology;2023-11-13

5. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen;CPT: Pharmacometrics & Systems Pharmacology;2022-12-05